Publication: 4575

Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations
Google Scholar   
Citation:
Year:
2026
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Preliminary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
15
Parents:
4265   4410  
Children:
None
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
   
Pharmas:
AstraZeneca, Eli Lilly, GSK  
Grants:
U10CA180821, U10CA180882; UG1CA189960, UG1CA189824, UG1CA232760, UG1CA233180, UG1CA233184, UG1CA233290, UG1CA233329; U10CA180868, UG1CA189867 (NRG Oncology)  
Corr. Author:
 
Authors:
                                                           
Networks:
COLUMBIA, CRCWM, IA018, IL043, LAPS-CT018, LAPS-IL036, LAPS-MA036, LAPS-MN026, LAPS-NH012, LAPS-NY016, LAPS-PA015, LAPS-TX011, NC002, NEWMEXICO, NY018, VA002, VT004   
Study
Alliance-A071401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: